US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Nearly 50 leading investigators affiliated with US Oncology
Research to participate in four posters and three poster
discussions
THE WOODLANDS, Texas, Dec. 1, 2011 /PRNewswire/ -- World-class
investigators affiliated with US Oncology Research participated in
studies that will be presented, discussed and displayed Dec. 6-10
at the Henry B. Gonzales Convention Center during the 2011
CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), an
international scientific symposium for interaction and exchange
among basic scientists and clinicians in breast cancer.
(Logo: http://photos.prnewswire.com/prnh/20110912/DA65711LOGO)
Joyce O'Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research, and medical oncologist with Texas Oncology-Baylor Sammons Cancer Center, will present her study findings in an oral presentation at 10:30 am CST, Thursday, Dec. 8.
The study titled "Next Generation Sequencing Reveals Co-Activating Events in the MAPK and PI3K/AKT Pathways in Metastatic Triple Negative Breast Cancers" provides an in-depth look at targeted therapies. Drs. Joanne Blum, Cynthia Osborne and Daniel Von Hoff, also physicians affiliated with US Oncology Research, participated in this innovative study.
In addition to the above oral presentation, nearly 50 US Oncology Research affiliated investigators participated in the following studies that will be displayed as posters and poster discussions at the conference:
?Poster Discussions:
?5:00-7:00 pm CST, Wednesday, Dec. 7 (Ballroom A): Randomized Phase
II Trial of Fulvestrant with or without Dasatinib in Postmenopausal
Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Previously Treated with an Aromatase Inhibitor - Wright GL, Blum
JL, Krekow LK, McIntyre KJ, Wilks ST, Rabe AC, Vukelja SJ, Andersen
JC, Wang Y, Asmar L, O'Shaughnessy J
?5:15-7:00 pm CST, Thursday, Dec. 8 (Ballroom B): Primary and
secondary pegfilgrastim utilization in adjuvant chemotherapy for
breast cancer in the community - Patt, DA, Espirito, JL, Turnwald,
B, Hoverman JR, Neubauer MA, Busby LT, Brooks BD, Kolodziej MA,
Anderson RW, Beveridge RA
?7:00-9:00 am CST, Friday, Dec. 9 (Ballroom A): Phase II Trial of
Adjuvant TC (Docetaxel/Cyclophosphamide) plus Trastuzumab (HER TC)
in HER2-Positive Early Stage Breast Cancer Patients - Jones S,
Collea R, Paul D, Oratz R, Sedlacek S, Favret A, Gore Jr. I,
Lindquist D, Holmes FA, Allison MAK, Steinberg MS, Stokoe C,
Portillo R, Crockett M, Wang Y, Asmar L, Robert N, O'Shaughnessy
J
?Posters:
?5:00-7:00 pm CST, Friday, Dec. 9 (Exhibit Halls A-B): The
Incidence of Febrile Neutropenia in the First Course of Adjuvant
Chemotherapy with Docetaxel/Cyclophosphamide with or without
Pegfilgrastim - Jones S, Paul D, Sedlacek S, Vukelja S, Wilks S,
Stokoe C, Osborne C, Krekow L, McIntyre K, Holmes FA, Zhan F,
Guerra L, Asmar L, O'Shaughnessy J, Blum J
?5:00-7:00 pm CST, Friday, Dec. 9 (Exhibit Halls A-B): Phase II
Trial of Ixabepilone plus Carboplatin in Patients with Metastatic
Breast Cancer: The ECLIPSE Study - Osborne C, Challagalla JD,
Fanning SR, Eisenbeis CF, Holmes FA, Monaghan GG, Neubauer MA, Rabe
AC, Raja V, Robbins GJ, Taboada CA, Vukelja SJ, Wilks ST, Wang Y,
Brown JA, Asmar L, O'Shaughnessy J
?5:00-7:00 pm CST, Friday, Dec. 9 (Exhibit Halls A-B): Correlation
of Clinical and Molecular Findings with Pathologic Response to
Preoperative Lapatinib and Trastuzumab, Separately or in
Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive
Breast Cancer - Holmes FA, Espina V, Liotta LA, Chang JC, Nagarwala
YX, Danso M, McIntyre K, Osborne CR, Krekow LK, Gagnon RC, Mahoney
JM, O'Shaughnessy JA
?5:00-7:00 pm CST, Friday, Dec. 9 (Exhibit Halls A-B): Pooled
Analysis of Individual Patient Data from Capecitabine Monotherapy
Clinical Trials in Anthracycline-/Taxane-Pretreated Locally
Advanced or Metastatic Breast Cancer (LA/MBC) - Blum JL, Barrios
CH, Feldman N, Verma S, McKenna E, Lee S, Scotto N, Gralow J
Many clinical studies led by US Oncology Research affiliated
physicians were and will also be prominently featured this year at
numerous conferences held around the world, including the annual
congress for the European Society for Medical Oncology (ESMO), the
annual meeting for the American Society for Clinical Oncology
(ASCO) and the American Society of Hematology (ASH) Annual Meeting
and Exposition. Those studies, along with more than 72 published
investigator-initiated manuscripts, featured forward looking
clinical research topics that are helping advance cancer care today
and discover improved therapies for the cancer care of tomorrow.
For a complete list, please contact US Oncology Research at
281-863-1000.
About US Oncology Research
McKesson Specialty Health conducts clinical trials through US Oncology Research, which draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in over 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 50,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.
About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckessonspecialtyhealth.com.
SOURCE McKesson Specialty Health
Posted: December 2011
